8th Apr 2022 12:30
Ideagen PLC
("Ideagen," "the Company" or the "Group'')
Exercise of Options and Total Voting Rights
Ideagen PLC (AIM: IDEA), a leading supplier of Information Management Software to highly regulated industries, announces that, following the exercise of options by an employee of the Company, it has issued a total of 45,000 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares").
Application has been made to the London Stock Exchange for the 45,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 14th April 2022.
Following the exercise of options, the total number of Ordinary Shares in issue will be 293,745,252 and the total number of voting rights will therefore be 293,745,252. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Enquiries:
Ideagen plc | 01629 699 100 |
Ben Dorks, Chief Executive Officer | |
Emma Hayes, Chief Financial Officer
| |
Canaccord Genuity Limited (Nomad) | 020 7523 8000 |
Simon Bridges | |
Georgina McCooke
| |
finnCap Limited | 020 7220 0500 |
Henrik Persson/James Thompson (Nomad) | |
Alice Lane (ECM) | |
Numis Securities Limited | 0207 260 1267 |
Simon Willis | |
Joshua Hughes | |
FTI Consulting | 020 3727 1000 |
Jamie Ricketts | |
Dwight Burden | |
Valerija Cymbal |
About Ideagen plc
Ideagen's software helps companies comply with regulation and manage risk.
Ideagen is a leader in the +$30 billion regulatory and compliance software market, serving highly regulated industries such as life sciences, healthcare, banking and finance and insurance.
More than 8,000 customers use Ideagen's software, including 9 of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of leading pharmaceutical firms.
Ideagen has a diversified customer base including blue chip, global brands such as Heineken, British Airways, BAE, Aggreko, US Navy, Bank of New York and Johnson Matthey, as well as 250 hospitals across the UK and US.
Ideagen is headquartered in the UK, listed on the London Stock Exchange AIM market (Ticker: IDEA.L), and has key hubs in the UK, USA, Middle East and South East Asia. For further information please visit www.ideagen.com.
Related Shares:
IDEA.L